Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.61 |
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | RAF1 | P04049 | 2/20 | 0.61 |
| ▸ | LYN | P07948 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.61 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.61 |
| ▸ | AKT1 | P31749 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086608 | 0.88 | MAPK14 (0.69) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4092169 | 0.87 | MAPK14 (0.68) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4096400 | 0.87 | MAPK14 (0.68) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4082201 | 0.86 | MAPK14 (0.68) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4081877 | 0.86 | MAPK14 (0.87) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4092580 | 0.85 | MAPK14 (0.67) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4096998 | 0.84 | MAPK14 (0.65) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4087465 | 0.84 | MAPK14 (0.66) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL27623368 | 0.84 | MAPK14 (0.66) | MAPK14MAPK9ABL1RAF1LYN | |
| SCHEMBL4085454 | 0.84 | MAPK14 (0.82) | MAPK14MAPK9ABL1RAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | MOSS NEIL | 2007-07-05 | — | — | US | claimed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | claimed |
| US-7211575-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | claimed |
| CN-1838958-A | method for treating chronic obstructive pulmonary disease and pulmonary hypertension | BOEHRINGER INGELHEIM FRANCE (US) | 2006-09-27 | — | — | CN | claimed |
| EP-1690854-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1658060-A2 | METHODS OF TREATING COPD AND PULMONARY HYPERTENSION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| WO-2005018624-A2 | METHODS OF TREATING COPD AND PULMONARY HYPERTENSION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | claimed |
| CN-1511830-A | Compound used as antiphlogistic | ���ָ��.Ӣ��ķҩ�﹫˾ | 2004-07-14 | — | — | CN | claimed |
| EP-1427412-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-06-16 | — | — | EP | claimed |
| US-6660732-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | claimed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | claimed |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | TNF, IL2, IL1B | MAPK14 922/4885MAPK9 1508/4885ABL1 2843/4885 |
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | PTGIS, PTGS1, MAPKAPK5 | MAPK14 55/4885MAPK9 121/4885ABL1 2764/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | MAPK14 74/4885MAPK9 145/4885ABL1 1152/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885MAPK9 41/4885ABL1 719/4885 |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | TNF, IL2, IL1B | MAPK14 922/4885MAPK9 1508/4885ABL1 2843/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | MAPK14 2740/4885MAPK9 1739/4885ABL1 3659/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885MAPK9 41/4885ABL1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.